A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER

摘要

A novel pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from a group consisting of paclitaxel, docetaxel, doxorubicin or gemcitabine or a pharmaceutically acceptable salt thereof and at least one cyclin dependent kinase (CDK) inhibitor; wherein the said combination exhibits synergistic effects when used in the treatment of cancer. The invention also relates to a method for the treatment of cancer, using a therapeutically effective amount of the said combination.